Clinical trials: Neoplasm, Ovarian
Ovarian Cancer, Endometrium Cancer
Predictive Clinical and Biological Parameters in Gynecological Cancer
Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation
- Conditions
- Ovarian Cancer, Endometrium Cancer, Cervix Cancer
- Trial name
- GC-BIO (NCT01977274)
- Testing
- gynecological cancer
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Institut Paoli-Calmettes
Ovarian Cancer
Bevacizumab and Carboplatin for Patients With Ovarian Cancer
This is a phase II trial to investigate the effect of bevacizumab and carboplatin in patients with platin resistant ovarian cancer.
- Trial name
- NCT00744718
- Testing
- Bevacizumab, Carboplatin
- Where
- Denmark
- Volunteers
- 73 people
- Sponsor
- Vejle Hospital
Ovarian Cancer
Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer
This clinical trial will evaluate the efficacy and safety of chiauranib added to chemotherapy in patients with relapsed or refractory ovarian cancer, in the meantime, explore the pharmacokinetics characteristic after the combined…
- Trial name
- NCT03901118
- Testing
- chiauranib, etoposide, paclitaxel
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Polycystic Ovary Syndrome
Aerobic Training With and Without Resistance Training in Polycystic Ovarian Syndrome
Polycystic ovary syndrome (PCOS) characterized by a chronic disorder in ovulation along with hyperandrogenism has become one of the most common endocrine disorders in women of reproductive age with an estimated 5%-15% prevalence.
- Trial name
- NCT06198348
- Testing
- Aerobic Exercise, Aerobic Exercises with Resistance training
- Where
- Pakistan
- Volunteers
- 22 people
- Sponsor
- Riphah International University
B-cell Malignancies, Colorectal Cancer (CRC)
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
This is a Phase 1/2, open label study. Phase 1 consists of 2 parts. Part 1 is a dose-escalation assessment of the safety and tolerability of epacadostat administered with nivolumab in subjects with select advanced solid tumors…
- Conditions
- B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer
- Trial name
- NCT02327078
- Testing
- Nivolumab, Epacadostat, Chemotherapy
- Where
- 24 sites in United States, United Kingdom
- Volunteers
- 307 people
- Sponsor
- Incyte Corporation
Polycystic Ovarian Syndrome
Paleo Versus Healthy ADA Diets for Treatment of Polycystic Ovarian Syndrome (PCOS)
Polycystic ovary syndrome (PCOS) is a syndrome which includes elevated androgen levels, irregular menstrual cycles and insulin resistance.
- Trial name
- NCT02190097
- Testing
- Paleolithic diet, American Diabetes Association diet
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Refractory Malignant Solid Neoplasm, Osteosarcoma
AOH1996 for the Treatment of Refractory Solid Tumors
This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory).
- Conditions
- Refractory Malignant Solid Neoplasm, Osteosarcoma, Leiomyosarcomas, Synovial Sarcomas
- Trial name
- NCT05227326
- Testing
- PCNA Inhibitor AOH1996
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- City of Hope Medical Center
Mesothelioma, Pancreatic Cancer
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
This research is being conducted to determine the biodistribution of radiolabeled amatuximab in tumor and non-tumor tissues in subjects with mesothelin over expressing cancer including mesothelioma, pancreatic, ovarian or non…
- Conditions
- Mesothelioma, Pancreatic Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT01521325
- Testing
- Amatuximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Morphotek
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Hormone Receptor-Positive Breast, Gynecologic
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Background: Some types of cancer cells that have hormone receptors on their surfaces need the hormone estrogen to grow. The drug tamoxifen blocks estrogen from binding to the tumor cells, which helps to slow or stop the growth of…
- Conditions
- Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
- Trial name
- NCT01273168
- Testing
- Z-Endoxifen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Ovulation Induction
Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction
This is an open-label, prospective, randomized, controlled, multicentric, multinational, phase IV study to evaluate the use of Gonal-f in inducing ovulation in female subjects with chronic anovulation.
- Trial name
- NCT01081626
- Testing
- Recombinant FSH (follitropin alpha)
- Where
- 3 sites in Kuwait, Lebanon and 1 more
- Volunteers
- 310 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Ovarian Cancer
Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00964626
- Testing
- cisplatin, paclitaxel
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Russian Academy of Medical Sciences
Fallopian Tube Cancer, Ovarian Cancer
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to determine the effectiveness of imatinib mesylate in treating patients who have…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00039585
- Testing
- imatinib mesylate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Biliary Tract Cancer (BTC), Colorectal Cancer (CRC)
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
- Conditions
- Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC)
- Trial name
- NCT03314935
- Testing
- INCB001158, Oxaliplatin, Leucovorin
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 149 people
- Sponsor
- Incyte Corporation
Recurrent Ovarian Carcinoma
Helping Ovarian Cancer Patients Cope With Their Illness (HOPE)
This clinical trial compares the effect of the Helping Ovarian Cancer Patients Cope with Their Disease (HOPE) intervention to usual care for the reduction of hopelessness and helplessness in patients with ovarian cancer that has…
- Trial name
- NCT06666218
- Testing
- Behavioral Intervention, Electronic Health Record Review, Interview
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Ovarian Cancer, Testicular Germ Cell Tumor
Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002559
- Testing
- filgrastim, cisplatin, ifosfamide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epithelial Ovarian Cancer
Phase III Trial of Stage I Ovarian Cancer After Surgery
To compare the Overall survival of adjuvant chemotherapy versus observation in stage I epithelial ovarian cancer after comprehensive staging surgery
- Trial name
- NCT04063527
- Testing
- adjuvant chemotherapy
- Where
- 103 sites in Japan, South Korea
- Volunteers
- 360 people
- Sponsor
- Japanese Gynecologic Oncology Group
Ovarian Cancer, Peritoneal Carcinomatosis
Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients
The purpose of this study is to determine if NIF fluorescent imaging is an effective approach to detect the gross ovarian tumoral tissues and peritoneal implants in Ovarian cancer patients.
- Trial name
- OV-AP-ICG-IV (NCT01834469)
- Testing
- iv injection of ICG
- Where
- Belgium
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Jules Bordet Institute
Ovarian Cancer, Colorectal Cancer
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
This study is looking at the safety and tolerability of the experimental biological drug EMD 273066 when given with low dose cyclophosphamide to patients with recurring EpCAM positive ovarian, prostate, colorectal or non-small…
- Conditions
- Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
- Trial name
- NCT00132522
- Testing
- EMD 273066
- Where
- 5 sites in United States, Switzerland
- Volunteers
- 45 people
- Sponsor
- EMD Serono
Ovarian Cancer, Fallopian Tube Cancer
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
- Trial name
- NCT05287451
- Testing
- RIsk-Reducing Salpingectomy (RRS), Risk-Reducing Oophorectomy-RRO, Risk-Reducing Salpingo-Oophorectomy-RRSO
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.